HC Wainwright Forecasts Strong Price Appreciation for Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare (NASDAQ:SRTS - Free Report) had its target price raised by HC Wainwright from $11.00 to $12.00 in a report issued on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Sensus Healthcare's Q1 2025 earnings at $0.11 EPS, Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.10 EPS, Q4 2025 earnings at $0.16 EPS and FY2025 earnings at $0.44 EPS.

Several other brokerages have also recently issued reports on SRTS. Lake Street Capital initiated coverage on Sensus Healthcare in a research note on Friday, January 31st. They issued a "buy" rating and a $18.00 price objective on the stock. Maxim Group increased their target price on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Friday, November 15th.

Sensus Healthcare Trading Down 2.7 %

Shares of NASDAQ SRTS traded down $0.15 during midday trading on Monday, hitting $5.50. The company's stock had a trading volume of 305,901 shares, compared to its average volume of 434,328. The business's 50 day moving average is $7.22 and its two-hundred day moving average is $6.88. Sensus Healthcare has a 12-month low of $2.91 and a 12-month high of $9.33. The firm has a market cap of $90.15 million, a P/E ratio of 13.75 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, analysts predict that Sensus Healthcare will post 0.71 earnings per share for the current fiscal year.

Institutional Trading of Sensus Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP lifted its holdings in shares of Sensus Healthcare by 99.6% during the 4th quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock valued at $915,000 after purchasing an additional 65,994 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $109,000. CreativeOne Wealth LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $155,000. Barclays PLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $35,000. Finally, Renaissance Technologies LLC raised its stake in Sensus Healthcare by 5.3% in the 4th quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after acquiring an additional 21,600 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company's stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.